Globalization Centered on Asia and Expansion into Emerging Markets
First written in FY2016. 32 of 43 entries say "Advanced", first in FY2017-Q1. Latest entry: FY2027-H1.
22 other companies' latest entry also says "Advanced".
- FY2027-H1AdvancedAnnual report
「(Asia) Sales to external customers increased substantially to ¥67.16 billion, up 17.1% year on year. In addition to the strong performance of Eu Yan Sang International Ltd., China and Southeast Asian countries such as Vietnam and Malaysia continued to perform well.」
Sales to external customers in Asia increased 17.1% year on year, with Eu Yan Sang International Ltd., China, Vietnam and Malaysia, among others, contributing to higher revenue. - FY2026AdvancedAnnual report
「With overseas operations accounting for approximately half of total sales and covering more than 120 countries as of 31 March 2026, we will continue to pursue higher corporate value by remaining rooted in local markets and engaging with consumers.」
The overseas business expanded its coverage from more than 110 countries to more than 120, while Eu Yan Sang International Ltd. also began contributing to sales in Asia. - FY2026-H1AdvancedAnnual report
「(Asia) Sales to external customers increased substantially to ¥57.348 billion, up 51.3% year on year. Southeast Asia, including Vietnam and Indonesia, continued to perform well. In addition, Eu Yan Sang International Ltd. contributed to sales.」
Sales to external customers in Asia increased 51.3% year on year, with strong performance in Southeast Asia and the consolidation and sales contribution of Eu Yan Sang International Ltd. progressing. - FY2025-H1AdvancedAnnual report
「Skin care currently accounts for 65% of sales by product and service, but further strengthening OTC medicines and food products is essential to providing solutions for all aspects of health. Asia, which accounts for approximately 30% of sales by region, is expected to achieve further growth. By combining Eu Yan Sang International Ltd.'s strong products and brands in Asia with the company's research, technology development and sales capabilities, the company aims to create an innovative business and realize an unprecedented health-care business.」
The report describes the composition of sales in Asia and the specific global expansion strategy centered on Asia, leveraging Eu Yan Sang International Ltd.'s products and brand strength. - FY2024AdvancedAnnual report
「The overseas business, which accounts for approximately 40% of total sales and covered more than 110 countries as of the end of March 2024, will continue seeking to increase corporate value by becoming rooted in local markets and engaging with consumers. In particular, the company will promote the introduction of OTC eye drops, skin-care products and oral medicines. It will actively invest management resources primarily in Asia, including China and Southeast Asia, where business is highly compatible with Japan, while seeking to maintain and expand its business in Europe and the Americas through the formulation and execution of the growth strategy for its subsidiary Mentholatum.」
The company has specified the regions covered by its overseas business, the products to be introduced and the allocation of management resources by region. Hong Kong, Taiwan and Indonesia, among others, sustained strong growth in Asia, while Europe and the Americas also recorded higher revenue. - FY2024-Q3China deteriorated while Hong Kong, Indonesia and Taiwan sustained strong growthAnnual report
「Although China was affected by worsening economic conditions, Hong Kong, Indonesia and Taiwan sustained strong growth. By product, sunscreen, eye drops, Hada Labo and the anti-dandruff shampoo Selsun contributed to higher revenue.」
In Asia, China was affected by worsening economic conditions, while Hong Kong, Indonesia and Taiwan continued to achieve strong growth. By product, sunscreen, eye drops, Hada Labo and Selsun contributed to higher revenue. - FY2024-Q2AdvancedAnnual report
「Hong Kong, Malaysia and Taiwan sustained strong growth, while China showed signs of recovery from the COVID-19 pandemic and drove sales. Lip balm, sunscreen, the anti-dandruff shampoo Selsun and eye drops contributed to higher revenue.」
In Asia, strong growth continued in Hong Kong, Malaysia and Taiwan, while China also showed signs of recovery. Sales to external customers in Asia amounted to ¥34.223 billion, up 15.3% year on year. - FY2024-Q1AdvancedAnnual report
「Although raw material prices rose overseas as well, revenue increased due to product proposals tailored to customer needs and the impact of the weaker yen.」
The overseas business recorded higher revenue, driven in part by product proposals tailored to customer needs, indicating progress in global expansion. - FY2023AdvancedAnnual report
「The overseas business, which accounts for approximately 40% of total sales and covered more than 110 countries as of the end of March 2023, will continue seeking to increase corporate value by becoming rooted in local markets and engaging with consumers. In particular, the company will promote the introduction of OTC eye drops and skin-care products. It will actively invest management resources primarily in Asia, including China and Southeast Asia, where business is highly compatible with Japan, while seeking to maintain and expand its business in Europe and the Americas through the formulation and execution of the growth strategy for its subsidiary Mentholatum.」
The company operates overseas in more than 110 countries, with a focus on investment of management resources in Asia, the introduction of OTC eye drops and skin-care products, and the growth strategy for Mentholatum in Europe and the Americas. - FY2023-Q3AdvancedAnnual report
「Overseas operations also recorded higher sales, despite higher raw-material prices, due to the recovery in economic activity and the impact of the weaker yen.」
The overseas business recorded higher revenue in all regions, including the Americas, Europe and Asia. The Americas increased 84.5% year on year, Europe 20.7% and Asia 30.8%, indicating progress in global expansion. - FY2023-Q2AdvancedAnnual report
「(Asia) Sales to external customers increased substantially to ¥29.673 billion, up 23.3% year on year.」
Sales to external customers in Asia increased 23.3% year on year, with the report noting recovery in China and Taiwan, strong growth in Malaysia and solid performance in Southeast Asia, including Vietnam and Indonesia. - FY2023-Q1AdvancedAnnual report
「Overseas sales also increased, despite higher raw-material prices and sharp currency fluctuations, due in part to the recovery in economic activity. China continued to increase sales despite lockdowns imposed in March under its zero-COVID policy, which affected markets and people's daily lives. Vietnam also achieved a V-shaped recovery as the economy recovered from the COVID-19 pandemic, while Indonesia remained strong.」
The report describes higher revenue in China despite lockdowns, a V-shaped recovery in Vietnam and strong performance in Indonesia, indicating progress in overseas expansion centered on Asia. - FY2022-Q3AdvancedAnnual report
「Sales to external customers increased substantially to ¥39.553 billion, up 20.3% year on year. Eye drops performed well, supported by the launch of new products and active promotional activities. Skin problems associated with mask wearing under the new normal increased, and the acne treatment Acnes and men's cosmetics also continued to perform well. China and Hong Kong continued to perform well as the economy recovered from the COVID-19 pandemic, while Vietnam's growth stalled due to its lockdown policy and the resulting factory shutdowns.」
Sales to external customers in Asia increased 20.3% year on year, supported by the recovery in China and Hong Kong and new products and promotional activities. In contrast, growth in Vietnam stalled due to its lockdown policy and factory shutdowns, revealing regional differences. - FY2022-Q2AdvancedAnnual report
「(Asia) Sales to external customers increased substantially to ¥24.057 billion, up 24.4% year on year. Eye drops performed well, supported by the launch of new and promotional products.」
Sales to external customers in Asia increased 24.4% year on year, with the launch of new and promotional products, the acne treatment Acnes and a recovery in men's cosmetics contributing to higher revenue. - FY2022-Q1AdvancedAnnual report
「Revenue from external customers rose sharply to ¥10,844 million, up 30.7% year on year. As the decline in COVID-19 cases increased opportunities for people to go outdoors, sunscreen, lip balm and eye drops recovered and performed well. Demand for the Acnes acne treatment surged because of skin problems associated with mask wearing. In China, the core market, the impact of COVID-19 gradually eased and the business showed strong growth.」
Sales to external customers in Asia increased 30.7% year on year, with the report noting a recovery from the impact of COVID-19 in China and increased demand for Acnes and other products. - FY2021China recovering and ASEAN remaining steady amid lower revenue across overseas regionsAnnual report
「Overseas, all regions recorded lower revenue because of the global spread of COVID-19.」
For the full year, overseas regions generally recorded lower revenue, while Taiwan returned to economic activity, ASEAN countries such as Indonesia and Vietnam remained steady, and China showed signs of recovery in eye drops and products such as 50 Megumi. - FY2021-Q3China recovering and ASEAN remaining steady amid lower revenue across overseas regionsAnnual report
「Revenue in Taiwan and other markets that effectively controlled the impact of COVID-19 was recovering toward normal economic activity, while Indonesia, Vietnam and other ASEAN countries also performed steadily. In China, the core market, revenue fell sharply in the first half, but from the second half onward, skincare-related products such as eye drops and 50 Megumi showed signs of recovery, although lip balm remained weak.」
Although overseas regions as a whole recorded lower revenue, the report notes divergent regional trends, including Taiwan's return to economic activity, steady performance in ASEAN countries and a recovery in skin-care products in China from the second half onward. - FY2021-Q2Lower revenue across all overseas regions, with China recoveringAnnual report
「Overseas, all regions recorded lower revenue because of the global spread of COVID-19.」
Although each overseas region recorded lower revenue, the report notes Taiwan's return to economic activity, steady domestic sales in Vietnam and signs of recovery in China, indicating divergent trends by region. - FY2021-Q1ASEAN revenue growth secured despite lower revenue in ChinaAnnual report
「Although Indonesia, Vietnam and other ASEAN countries recorded revenue growth, the Asian segment as a whole posted a significant decline in revenue because its core market, China, suffered a sharp downturn due to the impact of COVID-19.」
Although revenue increased in ASEAN countries, a significant decline in revenue in China due to the impact of infectious diseases resulted in regional differences, with Asia as a whole recording lower revenue. - FY2020AdvancedAnnual report
「Although overseas operations were affected by demonstrations in Hong Kong and the spread of COVID-19, strong performance in ASEAN countries such as Vietnam and Malaysia offset the impact.」
Overseas sales accounted for 39.0% of consolidated sales, with ASEAN countries such as Vietnam and Malaysia supporting higher revenue despite the impact of the Hong Kong protests and infectious diseases. - FY2020-Q3AdvancedAnnual report
「Sales to external customers amounted to ¥36.371 billion, up 2.0% year on year. Although sales were affected by the Hong Kong protests and boycotts of Japanese products in South Korea, eye drops and sunscreen performed steadily. The Hada Labo series also performed well in ASEAN countries such as Vietnam and Malaysia.」
Sales to external customers in Asia increased 2.0% year on year, with the Hada Labo series performing well in ASEAN countries such as Vietnam and Malaysia. - FY2020-Q2AdvancedAnnual report
「Revenue from external customers was ¥22,403 million, up 6.4% year on year. Despite concerns about an economic slowdown in China resulting from prolonged US-China trade tensions, eye drops and sunscreen performed steadily. The expansion of the Hada Labo brand into Vietnam and other ASEAN countries also contributed to revenue growth.」
Sales to external customers in Asia increased 6.4% year on year, with the expansion of the Hada Labo brand in ASEAN countries such as Vietnam also contributing to higher revenue. - FY2020-Q1AdvancedAnnual report
「Revenue from external customers was ¥10,591 million, up 7.3% year on year. Despite concerns about an economic slowdown in China resulting from US-China trade tensions, eye drops and men's cosmetics performed steadily, and Vietnam and other ASEAN countries also contributed to revenue growth.」
Revenue from external customers in Asia increased 7.3% year on year, and ASEAN countries including Vietnam contributed to higher revenue despite concerns about China. - FY2019-Q3AdvancedAnnual report
「Meanwhile, overseas operations remained solid in Asia despite concerns about the impact of US-China trade friction. The United States and Europe also contributed to higher revenue.」
Asia performed steadily despite concerns about US-China trade friction, while the United States and Europe contributed to higher revenue. The company describes regional progress in its global expansion. - FY2019-Q2AdvancedAnnual report
「Revenue from external customers was ¥21,058 million, up 15.8% year on year. Sales of lip balm and sunscreen products were strong, while eye drops also performed steadily. By country, sales in China were solid, and ASEAN countries including Indonesia also performed steadily.」
The company reports specific progress in Asia, where revenue from external customers increased 15.8% year on year and China and ASEAN countries including Indonesia performed steadily. - FY2019-Q1AdvancedAnnual report
「Revenue from external customers was ¥9,874 million, up 17.3% year on year. Sunscreen performed well and eye drops also performed steadily. By country, revenue in China recovered, while Indonesia and other ASEAN countries also performed steadily.」
Revenue in Asia increased 17.3% year on year, with the company describing a recovery in China and solid performance in ASEAN countries including Indonesia. The United States and Europe also contributed to higher revenue. - FY2018-Q3AdvancedAnnual report
「Overseas, the recovery trend in Asia continued, while the United States and Europe also contributed to revenue growth.」
The recovery trend in Asia continued, and the United States and Europe contributed to higher revenue, indicating improvement and progress in global expansion. - FY2018-Q2AdvancedAnnual report
「The recovery trend in China has continued in overseas markets, and the United States and Europe contributed to higher revenue.」
The company describes improvement and progress in its overseas operations, stating that the recovery trend in China continued and that the United States and Europe contributed to higher revenue. - FY2018-Q1AdvancedAnnual report
「The recovery trend in China has also become more pronounced in overseas markets, and the United States contributed to higher revenue.」
The company states that the recovery in sales in China has become more pronounced and that the United States also contributed to higher revenue, indicating concrete improvement in its overseas operations. - FY2017RestatedAnnual report
「The Group has promoted expansion in Asia and emerging markets from an early stage, and will continue to strengthen these efforts. It will also actively recruit overseas personnel, including researchers, to accelerate the pace of globalization.」
The company indicates a policy of continuing to strengthen expansion in Asia and emerging markets and accelerating globalization by hiring overseas personnel. - FY2017-Q3RestatedAnnual report
「Although Vietnam, Indonesia and other ASEAN countries performed well, revenue declined in China because of the deteriorating economic environment and intensifying competition.」
The company describes the regional situation, with strong performance in ASEAN countries and declining revenue in China, reaffirming the continued progress of its Asia-centered global expansion. - FY2017-Q2RestatedAnnual report
「Although Vietnam, Indonesia, and other markets performed well, revenue declined in China because of deteriorating economic conditions and intensified competition.」
Asia operations were strong in Vietnam and Indonesia, while revenue declined in China because of deteriorating economic conditions and intensified competition, resulting in uneven progress in global expansion by region. - FY2017-Q1AdvancedAnnual report
「Vietnam, Indonesia and other markets performed well, resulting in revenue growth of approximately 20% on a local-currency basis.」
Regarding expansion into emerging Asian markets, the company reports specific progress in Vietnam and Indonesia, where revenue increased by approximately 20% on a local-currency basis. China, meanwhile, struggled amid slowing economic activity. - FY2016First statedAnnual report
「The company is also accelerating the globalization of its business. Following growth in Asian markets such as China and Vietnam, it will actively pursue expansion into emerging markets where further growth is expected. It is also continuing to expand actively in the United States and Europe so that the Group can realize synergies.」
The company says it will pursue expansion into emerging markets and realize group synergies in the United States and Europe, based on growth in Asia, including China and Vietnam.